In the high-stakes arena of cancer drug development, SU212 was engineered as a safer twist on podophyllotoxin—a toxic killer designed to halt rogue cell division. Yet in a twist worthy of scientific serendipity, it veered off course, bypassing its intended target entirely and stumbling upon a superior mark. SU212 starves aggressive cancers, slashing growth with scant harm to healthy cells. This off-script pivot echoes drug history's happy accidents. Let's talk about how luck can lead to scientific breakthroughs.